Ablation vs medical therapy in the setting of symptomatic atrial fibrillation and left ventricular dysfunction

Congestive Heart Failure

Volumn 16, Issue 1, 2010, Pages 10-14

  Choi, Andrew D ^a   Hematpour, Khashayar ^a   Kukin, Marrick ^a   Mittal, Suneet ^a   Steinberg, Jonathan S ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN;

ADULT; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; TREATMENT RESPONSE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; CATHETER ABLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY VEINS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 74549158774     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00116.x     Document Type: Article

References (20)

1. Clark DM, Plumb VJ, Epstein AE. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997, 30:1039-1045.
2. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog Cardiovasc Dis. 2006, 48:256-269.
3. Hagens VE, Crijns HJ, Van Veldhuisen DJ. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005, 149:1106-1111.
4. Olsson LG, Swedberg K, Ducharme A. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006, 47:1997-2004.
5. Herweg B, Sichrovsky T, Polosajian L. Anatomic substrate, procedural results, and clinical outcome of ultrasound-guided left atrial-pulmonary vein disconnection for treatment of atrial fibrillation. Am J Cardiol. 2005, 95:871-875.
6. Wazni OM, Marrouche NF, Martin DO. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005, 293:2634-2640.
7. Oral H, Pappone C, Chugh A. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006, 354:934-941.
8. Hsu LF, Jais P, Sanders P. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004, 351:2373-2383.
9. Tondo C, Mantica M, Russo G. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin Electrophysiol. 2006, 29:962-970.
10. Chen MS, Marrouche NF, Khaykin Y. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004, 43:1004-1009.
11. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol. 1998, 32:205-210.
12. Morady F, Hasse C, Strickberger SA. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol. 1997, 29:113-121.
13. Lee SH, Chen SA, Tai CT. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol. 1998, 31:637-644.
14. Khan MN, Jais P, Cummings J. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008, 359:1778-1785.
15. Kaseda S, Zipes DP. Contraction-excitation feedback in the atria: a cause of changes in refractoriness. J Am Coll Cardiol. 1988, 11:1327-1336.
16. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol. 1996, 7:833-842.
17. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 1997, 96:1686-1695.
18. Wyse DG, Waldo AL, DiMarco JP. A comparison of rate versus rhythm control in patients with atrial fibrillation. N Engl J Med. 2002, 347:1825-1833.
19. Mason PK, Wood MA, Lake D. Influence of the randomized trials, AFFIRM and RACE, on the management of atrial fibrillation in two University Medical Centers. Am J Cardiol. 2005, 95:1248-1250.
20. Roy D, Talajic M, Nattel S. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008, 358:2667-2677.